

Corrigendum


**Corrigendum to “Synthetic studies on novel Syk inhibitors.
Part 1: Synthesis and structure–activity relationships
of pyrimidine-5-carboxamide derivatives”
[Bioorg. Med. Chem. 13 (2005) 4936–4951]**

Hiroyuki Hisamichi,^{a,*} Ryo Naito,^a Akira Toyoshima,^b Noriyuki Kawano,^a
Atsushi Ichikawa,^a Akiko Orita,^a Masaya Orita,^a Noritaka Hamada,^a Makoto Takeuchi,^a
Mitsuaki Ohta^a and Shin-ichi Tsukamoto^a


^a*Institute for Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan*

^b*Department of Clinical Development, Astellas Pharma Inc., 3-17-1 Hasune, Itabashi, Tokyo 174-8612, Japan*


The legends to Schemes 1, 2, and 3 do not correspond to their respective schemes. The correct schemes and legends appear on the following two pages.



Scheme 1. Reagents and conditions: (a) 3-trifluoromethylaniline, ⁱPr₂NEt, MeCN; (b) 1 M NaOH, MeOH; (c) aq NH₃, EDCI, HOBT, ClCH₂CH₂Cl.



Scheme 2. Reagents and conditions: (a) ArNH₂, ⁱPr₂NEt, MeCN; (b) 1 M NaOH, MeOH or THF; (c) aq NH₃, EDCI, HOBT, ClCH₂CH₂Cl or DMF; (d) R²R³NH, MeCN; (e) 4 N HCl/AcOEt, EtOH.



Scheme 3. Reagents and condition: (a) R⁴NH₂, ⁱPr₂NEt, MeCN; (b) 1 M NaOH, MeOH; (c) R⁵R⁶NH, EDCI, HOBT, ClCH₂CH₂Cl or DMF; (d) R²NH₂, MeCN.